Abstract
Purpose: To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician.
Patientsandmethods: Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized phase III trial (Japan Clinical Oncology Group (JCOG) Study 8808) were asked whether they understood their own disease after being given information about the clinical trial. They were classified into two groups on the basis of whether they understood or not. We estimated their survival after the time of registration and derived relative hazard ratios from Cox's proportional hazards model.
Results: There were 190 patients in the ‘better understanding’ group and 24 in the ‘poor understanding’ group. Median survival times after registration were 28.3 and 16.1 months, respectively. The ‘better understanding’ group showed a significant difference from the ‘poor understanding’ group (p=0.016). In multivariate regression analysis, patients who did not understand still showed poorer survival than those who understood (hazard ratio = 2.09; 95% confidence interval (CI) 1.16–3.78; p=0.014)
Similar content being viewed by others
References
Meredith C, Symonds P, Webster L, Lamont D, Pyper E, Gillis CR, Fallowfield L: Information needs of cancer patients in west Scotland: cross sectional survey of patients' views. BMJ 313: 724–726, 1996
Meisel A, Kuczewski M: Legal and ethical myths about informed consent. Arch Intern Med 156: 2521–2526, 1996
Appelbaum PS, Grisso T: Capacities of hospitalized, medically ill patients to consent to treatment. Psychosomatics 38: 119–125, 1997
Williams CJ, Zwitter M: Informed consent in European multicentre randomised clinical trials - Are patients really informed? Eur J Cancer 30A: 907–910, 1994
Wise J: Patients do not read consent forms. BMJ 313: 1421, 1996
Maunsell E, Brisson J, Deschenes L: Social support and survival among women with breast cancer. Cancer 76: 631–637, 1995
Pettingale KW, Morris T, Greer S, Haybittle JL: Mental attitudes to cancer: An additional prognostic factor. Lancet 1: 750, 1985
Spiegel D, Bloom JR, Kraemer HC, Gottheil E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2: 888–891, 1989
Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL: Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 50: 681–689, 1993
House JS, Landis KR, Umberson D: Social relationships and health. Science 241: 540–545, 1988
Spiegel D: Psychosocial intervention in cancer. J Natl Cancer Inst 85: 1198–1205, 1993
Richardson JL, Shelton DR, Krailo M, Levine AM: The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 8: 356–364, 1990
Slevin ML, Nichols SE, Downer SM, Wilson P, Lister TA, Arnott S, et al.: Emotional support for cancer patients: What do patients really want? Br J Cancer 74: 1275–1279, 1996
Bloom JR: Social support, accommodation to stress and adjustment to breast cancer. Soc Sci Med 16: 1329–1338, 1982
Akechi T, Okamura H, Yamawaki S, Uchitomi: Predictors of patients' mental adjustment to cancer: patient characteristics and social support. Br J Cancer 77: 2381–2385, 1998
Watson M, Greer S, Young J, Inayat Q, Burgess C, Robertson B: Development of a questionnaire measure of adjustment to cancer: the MAC scale. Psychol Med 203–209, 1988
Watanabe T, Adachi I, Tajima K, Aoyama H, Sano M, Nomura Y: Improving the quality of life during chemoendocrine therapy for metastatic breast cancer: A randomized comparison of tamoxifen (TAM) versus medroxyprogesterone acetate (MPA) in combination with doxorubicin (ADM) plus cyclophosphamide (CPA) (Abstract). Proc Am Soc Clin Oncol 13: 72, 1994
Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170, 1966
Cox DR: Regression models and life-tables. J R Stat Soc B 34: 187–200, 1972
Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Tokue Y, Narabayashi M, Adachi I, Takashima S: Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16: 2401–2408, 1998
Hopper KD, TenHave TR, Hartzel J: Informed consent forms for clinical and research imaging procedures: how much do patients understand? Am J Roentgenol 164: 493–496, 1995
Sugarman J, McCrory DC, Hubal: Getting meaningful informed consent from older adults: a structured literature review of empirical research. J Am Geriatr Soc 46: 517–524, 1998
Gajalakshmi CK, Shanta V, Swaminathan R, Sankaranarayanan R, Black RJ: A population-based survival study on female breast cancer in Madras, India. Br J Cancer 75: 771–775, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okamura, H., Yamamoto, N., Watanabe, T. et al. Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer. Breast Cancer Res Treat 61, 145–150 (2000). https://doi.org/10.1023/A:1006491417791
Issue Date:
DOI: https://doi.org/10.1023/A:1006491417791